참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Acetamide | HCID 178 | — |
| 반응물 | Hydrogen Bromide | HCID 260 | — |
| 반응물 | Dimethyl Ether | HCID 8254 | — |
| 반응물 | Hydrogen iodide | HCID 24841 | — |
| 반응물 | L-Tyrosine, N-acetyl-3,5-diiodo-O-(4-methoxyphenyl)-, ethyl ester | HCID 10952191 | — |
| 생성물 | 3,5-Diiodothyronine, L- | HCID 92859 | — |
반응 단계
Many patent and non-patent literature describe the use of an intermediate called Bis (p-anisyl)iodonium bromide in the preparation of Levothyroxine sodium. Hillmann (Z. Naturforch 1956; 11b:424-425) describes a process for the assembly of the biphenyl-ether system present in Levothyroxine, wherein a key coupling reaction is initiated between N-Acetyl 3,5-diiodo-L-tyrosine ethyl ester, derived from the stepwise protective conversion of amine as amide and acid as ester of 3,5 diido-L-tyrosine, and Bis (p-anisyl)iodonium bromide in the presence of copper metal or powder as a catalyst to afford (S)—N-acetyl-3,5-diiodo-4-p-methoxyphenoxyphenylalanine ethyl ester, with 87% yield. All the three protective groups in (S)—N-acetyl-3,5-diiodo-4-p-methoxyphenoxyphenylalanine ethyl ester, viz. acetamide, methyl ether, ethyl ester were cleaved using a mixture of Hydroiodic acid and Hydrobromic acid to give 3,5-Diiodothyronine. 3,5-Diiodothyronine on subsequent iodination with iodine gave L-thyroxine of an yield that corresponds to 92%.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US09428444B2 |
|---|
| 출처 데이터셋 | uspto-grants-2016_08 |
|---|
| ORD ID | ord-19dc8d269fa84dfbaa970919e8c7f67c |
|---|
| 출처 메모 | uspto-grants-2016_08 |
|---|